Cholesterol goals unmet in adults entering oral drug trial
The 3,053 participants’ average “bad” cholesterol level was 2.30 mmol/L despite the most intensive oral cholesterol-lowering treatment they could tolerate.
Double-blind, placebo-controlled
Limit: Enrollment required elevated LDL cholesterol, selecting for unmet cholesterol goals
Edited by Boris Djordjevic · AgingResearch.News
AZURE-LDL enrolled 3,053 adults aged 18 or older who had experienced an event related to atherosclerotic cardiovascular disease—disease involving fatty buildup in arteries—or faced high risk of a first event. The randomized, double-blind trial assigned participants to oral laroprovstat or placebo alongside existing cholesterol-lowering medicines.
Preliminary baseline data showed that 59.4% had experienced a prior cardiovascular event. Overall, 79.1% were taking high-intensity statins, medicines that lower cholesterol. Mean low-density lipoprotein (LDL), often called “bad” cholesterol, was 2.30 mmol/L despite maximally tolerated oral therapy. The main outcome is the relative change in LDL cholesterol at 12 weeks. Follow-up lasts one year, with final results expected in 2027.
Why it matters
Cardiovascular disease is an age-related health concern. The trial asks whether adding an oral medicine can address cholesterol levels that remain above recommended goals despite existing treatment.
Caveats
This conference abstract reports preliminary baseline data, not treatment benefits or harms. The trial concerns adults with prior cardiovascular events or high cardiovascular risk, not lower-risk adults or children.
- Laroprovstat
- PCSK9
- Lipid and ceramide metabolism
- Atherosclerotic cardiovascular disease
- LDL cholesterol
- Humans
The paper
Amsterdam UMC Location University of Amsterdam; University of Colorado Anschutz
ESC Congress 2026 Abstract, Oct 26, 2026, Open access
Presented at ESC Congress 2026
Comments
Be the first to comment.